Rheumatology

Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.

Pediatric patients who had a referral from their pediatric rheumatologist and continued insurance coverage saw decreased delays when transitioning to an adult rheumatology clinic.

A survey from the American College of Rheumatology (ACR) revealed that patients with rheumatic diseases are struggling to get access to health care treatment.

Both patients with early and established psoriatic arthritis (PsA) have similar improvements in general health and mental well-being after treatment with secukinumab.

A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate response to anti–tumor necrosis factor therapies.

The Mediterranean diet, which is known to have health benefits, may help prevent rheumatoid arthritis (RA) in current or previous smokers, according to new research published in Arthritis & Rheumatology.

Comorbidities can have an impact on the main disease domains for patients with psoriatic arthritis. For each additional comorbidity a patient has, their disease activity score increases.

It may be possible to modify some lifestyle and environmental factors to reduce the risk of patients transitioning from psoriasis to psoriatic arthritis.

Cardiometabolic comorbidities are a considerable burden in patients with psoriatic arthritis, and patients who had a higher number of cardiovascular (CV) risk factors had greater disease activity, according to a study in Medicina.

The burden of disease in patients with axial psoriatic arthritis (PsA) can differ significantly between genders, according to a new study published in Modern Rheumatology.

Patients with psoriasis and psoriatic arthritis are at a greater risk for osteopenia and osteoporosis, but the associate is the result of secondary factors, such as medication.

The FDA rejects Gilead’s new drug application for filgotinib; new survey results on mental health care access for LGBTQ youth; Anthony S. Fauci, MD, thinks a mandatory coronavirus disease 2019 (COVID-19) vaccination is unlikely.

Secukinumab 150 mg improves signs and symptoms of patients with nonradiographic axial spondyloarthritis, according to results of the PREVENT trial published in Arthritis & Rheumatology.

The risk of orthopedic surgery has declined for patients with rheumatoid arthritis (RA) over the course of decades, but the same trend has not occurred for patients with psoriatic arthritis.

Most studies have evaluated PsA-associated fatigue in western populations. A new study has highlighted that PsA-associated fatigue is also prevalent in an Asian population and correlates with disease activity, impact, and chronicity.

New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.

Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis who were treated with secukinumab achieved minimal disease activity, as well as other improvements.

Patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular disease (CVD), because inflammation plays a pivotal role in the development of CVD. However, there is a need for greater improvement of CVD risk prevention.

During the coronavirus disease 2019 (COVID-19) pandemic, clinics have closed to varying degrees. As clinics look to reopen or welcome back patients after a COVID-19 infection, the American College of Rheumatology (ACR) has released advice on strategies for reopening practices as the pandemic continues.

Patients who have both skin and joint symptoms with psoriatic arthritis have greater disease burden and worse quality of life compared with patients who have joint-only involvement.

In children with inflammatory rheumatic diseases, tocilizumab can cause serious adverse events (AEs), with children who were younger at disease onset and at time of tocilizumab initiation especially affected.

In 2 studies of secukinumab use in real-world settings, researchers identified the usefulness of dose escalation in patients with psoriatic arthritis (PsA), as well as the safety, retention rate, and factors associated with drug survival among patients with PsA and ankylosing spondyloarthritis.

Psoriatic arthritis and psoriasis have high economic burdens and the total annual costs were similar between the 2 diseases, but the combination of both yielded the highest costs, according to an abstract published at the European League Against Rheumatism annual meeting.

Although early diagnosis of axial spondyloarthritis is crucial for patients to receive timely access to care and effective treatment, these patients experience a diagnostic delay of more than 7 years, on average.

Clinical trial result revealed that upadacitinib may be more effective in treating patients with rheumatoid arthritis than the gold standard of care, methotrexate.